COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,155 Articles (22,703 medRxiv, 8,452 bioRxiv)

Most recent first Previous |  Page 12: Articles 111-120  | Next

Genetic Diversity Drives the Rate and Fitness Jumps of Detectable SARS-CoV-2 Recombination
Smith, K., Gangwar, P., Wertheim, J. O., Turakhia, Y.
10.1101/2025.10.28.25338993 — Posted: 2025-10-30
Persistent Spike antigenemia is not associated with Post-COVID condition
Coppens, L., Gorska, A., Hotterbeekx, A., Canziani, L. M., Mateescu, V. O., Gentilotti, E., Pirici, D., Berkell, M., Orchestra Biomarker Study Group, , Malhotra, S., Tacconelli, E., Kumar-Singh, S.
10.1101/2025.10.24.25338528 — Posted: 2025-10-30
Human Coronavirus HKU1 Neutralizing Monoclonal Antibodies Target Diverse Epitopes Within and Around the TMPRSS2 Receptor Binding Site
Wang, L., Joseph, J., Vasquez, S., Wrapp, D., Sheahan, T. P., Dzuvor, C. K. O., Rosen, O., Kirchdoerfer, R., Abiona, O. M., Hammond, C., Shi, W., Moak, S. P., Kong, W.-P., Zhang, Y., Eso, M. R., Brown, A. J., Ward, A., Baric, R. S., McLellan, J. S., Pierson, T. C., Mascola, J., Graham, B. S., Yassine, H., Barnes, C. O., Corbett-Helaire, K. S.
10.1101/2025.10.29.685445 — Posted: 2025-10-30
Saved and lost: The Health impact of routine vaccination and COVID-19 related restrictions in Democratic Peoples Republic of Korea (1980~2024), a modelling study
Park, H., Carter, A., Choe, Y. J., Kirabo, S. J., Choi, M., Sohn, I., Han, J. H., Lee, Y. H.
10.1101/2025.10.28.25338937 — Posted: 2025-10-29
Assessment of Safety and Acceptance toward Covid-19 Vaccines: A cross-sectional Study in Egypt
Werida, R. H., Amralla, M. T., Bekhit, N. N., Youssef, M., Dogheim, G. M.
10.1101/2025.10.28.25338945 — Posted: 2025-10-29
Evolution and Viral Properties of the SARS-CoV-2 BA.3.2 Subvariant
Jule, Z., Romer, C., Hossen, T., Sviridchik, V., Reedoy, K., Ganga, Y., Norman, A., Silangwe, S., Karim, F., Kekana, D., Mahlangu, B., Mnguni, A., Nzimande, A., Stock, N., Bernstein, M., Gosnell, B., Moosa, Y., Wolter, N., Khan, K., Neher, R. A., Sigal, A.
10.1101/2025.10.28.25338622 — Posted: 2025-10-29
Recovery from post-COVID-19 condition and associated factors: the PRIME post-COVID study
Pagen-Arets, D. M. E., van Bilsen, C. J. A., Wijnen, S. M. C. E., den Heijer, C. D. J., Hoebe, C. J. P. A., Dukers-Muijrers, N. H. T. M.
10.1101/2025.10.28.25338941 — Posted: 2025-10-29
SwitchClass: dissecting attenuated and escalated molecular features via a label-switch classification framework
Xiao, D., Yang, P.
10.1101/2025.10.29.685265 — Posted: 2025-10-29
A Systematic Scoping Review and Conceptual Analysis of New-Onset Fibromyalgia Manifestations After Non-Hospitalized COVID-19: Empirics, Definitions, Methodologies, Pathophysiology, Mapping of Literature, and Knowledge Gaps
Plaut, S.
10.1101/2025.10.23.25338705 — Posted: 2025-10-28
Class switching toward IgG4 six months after primary mRNA-based COVID-19 vaccination in kidney patients
Frölke, S., Amirkhan, K., van der Bom-Baylon, N., van Gils, M., Claireaux, M., Geerlings, S., de Vries, R., Sanders, J.-S., Hilbrands, L., Diavatopoulos, D., Messchendorp, L., van Aalderen, M., Remmerswaal, E., Bemelman, F.
10.1101/2025.10.26.25338845 — Posted: 2025-10-28

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).